Back to Insights

Blue Matter Breakfast Club Meeting #2 – A Discussion with Nick Leschly, CEO of bluebird bio

Posted by Blue Matter on July 1st, 2019.

The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team.  These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues.

Blue Matter Breakfast Club 2, Nick Leschly, CEO of bluebird bio
Nick Leschly, CEO of bluebird bio, discussing gene therapies with attendees at Blue Matter’s 2nd “Breakfast Club” Meeting in Zug, Switzerland.

The second Breakfast Club meeting was on 17th June 2019 at Skylounge restaurant in Zug, Switzerland.  The guest speaker was Nick Leschly, CEO of bluebird bio.  Several key topics were raised and explored during this session, including:

  • How gene therapy is finally delivering breakthroughs after a decades-long journey
  • The interesting history and guiding purpose of bluebird bio
  • bluebird bio’s philosophy on the value and cost of therapies
  • The key challenges in unlocking the full commercial potential of gene therapies

Here, you can access an outline-based summary of the discussion:

Blue Matter Breakfast Club “Bottom Line” 2, 17 June 2019

We use cookies to provide website functionality and give you the best possible experience. Our Cookie Statement provides more information and explains how to amend your cookie settings.

By pressing the “Accept Cookies” button, the user accepts all Cookies on the Website. View our Cookie Statement.